Finoriq research workspace
Nuvation Bio Inc. (NUVB) Institutional Holdings & 13F Ownership
Track institutional investor activity, 13F holders, portfolio weights, and reported position changes for Nuvation Bio Inc. (NUVB).
Company Snapshot
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Company
- Nuvation Bio Inc. (NUVB)
- Ticker
- NUVB
- Market Cap
- $2.2B
- Latest Price
- $6.29
- Industry
- Biotech & Pharma
Nuvation Bio Inc. (NUVB) Top Institutional Holders
Top current 13F holders indexed for Nuvation Bio Inc. (NUVB). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Stanley DruckenmillerCIK 0001536411 | $19.5M | 0.58% | Filing2026-05-15 |
| 2 | David AbramsCIK 0001358706 | $5.5M | 0.12% | Filing2026-05-14 |
| 3 | David EinhornCIK 0001489933 | $150,129 | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.